CHRS - Coherus BioSciences Inc logo

Coherus BioSciences Inc

CHRS

Coherus BioSciences develops and commercializes biosimilars and immunotherapies for cancer treatment. Its key products include UDENYCA, LOQTORZI, and investigational monoclonal antibodies, targeting various oncological conditions in the U.S. market.

โš•๏ธ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago โ†’$40today

Score Overview

1 Year
Score
Net Growth23.10%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth20.78%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score5.0
Net Growth54.39%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-84.40%
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-2.84%
Net Trend60%
Net Income Consistency
Rev Growth-73.21%
Rev Trend57%
Revenue Consistency
All Time
Score
Net Growth-50.30%
Net Trend58%
Net Income Consistency
Rev Growth63.75%
Rev Trend56%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Coherus BioSciences Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. CHRS does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-09
$ 1.07โ€”
1 Year2025-10-09
$ 1.82-41.21%
5 Years2021-10-08
$ 18.04-94.07%
10 Years2016-10-07
$ 27.04-96.04%
All Time2014-11-06
$ 12.61-91.51%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 50M-$ 130M$ 105M
2025$ 42M-$ 170M$ 172M
2024$ 266M$ 28M$ 125M
2023$ 257M-$ 237M$ 117M
2022$ 211M-$ 291M$ 191M
2021$ 326M-$ 287M$ 417M
2020$ 475M$ 132M$ 541M
2019$ 356M$ 89M$ 177M
2018-$ 209M$ 72M
2017-$ 238M$ 126M
2016$ 190M-$ 127M$ 124M
2015$ 30M-$ 223M$ 158M
IPO2014$ 31M-$ 87M$ 150M
CHRS - Coherus BioSciences Inc logo

Coherus BioSciences Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 475M to $ 42M and net income went from $ 132M to -$ 170M. Revenue increased in 3 of those 5 years; net income in 3.

Between 2015 and 2025, revenue grew from $ 30M to $ 42M and net income went from -$ 223M to -$ 170M. Revenue increased in 6 of those 10 years; net income in 6.

Coherus BioSciences Inc currently holds a 5-year HDB Score of 5.0 out of 10. How the HDB Score is calculated.

Membership

Explore CHRS with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,126 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies